The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer
The DNA repair pathways contribute to HER2-directed ADC resistance. Our data justify exploring the combination treatment of T-DXd with DNA repair-targeting drugs to treat HER2-directed ADC-resistant HER2+ breast cancer in clinical trials.
Authors
- Lei Huo (ORCID: https://orcid.org/0000-0001-7533-9082)
- Young Jin Gi (ORCID: https://orcid.org/0000-0002-6549-0042)
- Jiwon Koh (ORCID: https://orcid.org/0000-0002-7687-6477)
- Kumiko Kida (ORCID: https://orcid.org/0000-0002-0946-5053)
- Jangsoon Lee (ORCID: https://orcid.org/0000-0002-6862-5686)
- Asha S. Multani (ORCID: https://orcid.org/0000-0002-6989-8627)
- Ayşegül A. Şahin (ORCID: https://orcid.org/0000-0001-8259-9624)
- Dileep R. Rampa (ORCID: https://orcid.org/0000-0003-3086-4822)
- Huey Liu (ORCID: https://orcid.org/0000-0002-0752-8348)
- Seock‐Ah Im (ORCID: https://orcid.org/0000-0002-5396-6533)
- Ganiraju C. Manyam
- Naoto Tada Ueno (ORCID: https://orcid.org/0000-0002-0166-7275)
- Jing Wang (ORCID: https://orcid.org/0000-0003-1618-2016)
- Dae-Won Lee
- Debu Tripathy (ORCID: https://orcid.org/0000-0002-5711-2404)
- James M. Reuben
- Gitanjali Jayachandran
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Seoul National University (KR)
- Cancer Research Institute (US)
- Seoul National University Hospital (KR)
- St. Luke's International Hospital (JP)
- Cancer Center of Hawaii (US)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1186/s13046-024-03143-3
- Citations
- 20
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 5.65
Funders
- Cancer Research Institute
- Cancer Prevention and Research Institute of Texas
- Seoul National University
- Daiichi-Sankyo
- Seoul National University Hospital
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- Daiichi Sankyo Company
- National Cancer Institute
- Daiichi Sankyo Europe